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Abstract:
BACKGROUND: All-oral combination therapy is desirable for
patients with chronic hepatitis C virus (HCV) infection. We evaluated
daclatasvir (an HCV NS5A replication complex inhibitor) plus sof-
osbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in
patients infected with HCV genotype 1, 2, or 3.
METHODS: In this open-label study, we initially randomly assigned
44 previously untreated patients with HCV genotype 1 infection and
44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose
of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally
once daily, with or without ribavirin, for 24 weeks. The study was
expanded to include 123 additional patients with genotype 1 infection
who were randomly assigned to daclatasvir plus sofosbuvir, with or
without ribavirin, for 12 weeks (82 previously untreated patients)
or 24 weeks (41 patients who had previous virologic failure with tela-
previr or boceprevir plus peginterferon alfa-ribavirin). The primary
end point was a sustained virologic response (an HCV RNA level of
<25 IU per milliliter) at week 12 after the end of therapy.
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Abbreviations: DAAs, direct-acting antivirals; HCV, hepatitis C virus; NI, nucleo-
side inhibitors; PegIFN, pegylated interferon; G, Genotype; QD, once daily; RBV,
ribavirin; SVR, sustained virological response.RESULTS: Overall, 211 patients received treatment. Among patients
with genotype 1 infection, 98% of 126 previously untreated patients
and 98% of 41 patients who did not have a sustained virologic
response with HCV protease inhibitors had a sustained virologic
response at week 12 after the end of therapy. A total of 92% of 26
patients with genotype 2 infection and 89% of 18 patients with geno-
type 3 infection had a sustained virologic response at week 12. High
rates of sustained virologic response at week 12 were observed
among patients with HCV subtypes 1a and 1b (98% and 100%, respec-
tively) and those with CC and non-CC IL28B genotypes (93% and 98%,
respectively), as well as among patients who received ribavirin and
those who did not (94% and 98%, respectively). The most common
adverse events were fatigue, headache, and nausea.
CONCLUSIONS: Once-daily oral daclatasvir plus sofosbuvir was
associated with high rates of sustained virologic response among
patients infected with HCV genotype 1, 2, or 3, including patients
with no response to prior therapy with telaprevir or boceprevir.
(Funded by Bristol-Myers Squibb and Pharmasset (Gilead);
A1444040 ClinicalTrials.gov number, NCT01359644.).
 2014 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under Introduction
There have been major advancements these past years with large
numbers of trials with various direct-acting antivirals (DAAs) oral
regimens showing increased SVR rates, favourable tolerability,
and shortened treatment duration [1–5]. These DAAs target mul-
tiple viral sites: NS3/4a protease, NS5B polymerase, and NS5A.
HCV regimens in Phase II or III, or already approved in 2014 are
listed in Table 1. This paper will comment on the recently pub-
lished phase IIb trial with daclatasvir plus sofosbuvir for HCV
Infection, reporting spectacular results [3].Daclatasvir
Daclatasvir is a ﬁrst-in-class HCV NS5A replication complex
inhibitor [6]. Daclatasvir is active at picomolar concentrations
in vitro in HCV replicons expressing a broad range of HCV14 vol. 61 j 435–438
Table 1. HCV regimens in phase II or III trials in 2014 or already approved.
Triple therapy
1 DAA + PegIFNα/RBV
IFN-free regimens
(phase II)
IFN-free regimens 
(phase III)
Telaprevir Simeprevir + sofosbuvir Sofosbuvir + RBV
Boceprevir Daclatasvir + sofosbuvir Sofosbuvir + ledipasvir ± RBV
Sofosbuvir Daclatasvir + simeprevir ABT-450/r + ombitasvir  ±  dasabuvir  ± RBV
Simeprevir Daclatasvir + asunaprevir + BMS 791325 Daclatasvir + asunaprevir
Faldaprevir MK 5172 + MK 8742 ± RBV
Daclatasvir
MK 5172
Danoprevir
Alisporivir
International Hepatologygenotypes and acts in an additive to synergistic fashion with
interferon (IFN) and other DAAs. The resistance proﬁle of dacla-
tasvir reveals inhibitor sensitivity maps to the N terminus of
domain 1 of NS5A. NS5A inhibitors could block hyperphosphory-
lation of NS5A, which is believed to play an essential role in the
viral replication cycle.Sofosbuvir
Sofosbuvir is a nucleotide analogue HCV NS5B polymerase inhib-
itor [7]. Polymerase inhibitors interfere with viral replication by
binding to the NS5B RNA-dependent RNA polymerase. Nucleoside
inhibitors (NI) mimic the natural substrates of the polymerase
and are incorporated into the RNA chain causing direct chain ter-
mination. NI require conversion to an active triphosphate form.
As the active site of NS5B is highly conserved, NI have generally
a pan-genotypic efﬁcacy. However, single amino acid substitu-
tions in every position of the active site may result in loss of func-
tion of NI, but resistance to NI is typically very low.Daclatasvir plus sofosbuvir study design and results
In this open-label study, 44 HCV genotype 1 (G1) naïve patients
and 44 HCV-G2 or G3 patients were initially randomly assigned
to daclatasvir (60 mg QD) plus sofosbuvir (400 mg QD), with or
without ribavirin (RBV), for 24 weeks [3]. The study was
expanded to include 123 additional HCV-G1 patients who were
randomly assigned to daclatasvir plus sofosbuvir, with or without
RBV, for 12 weeks (82 naïve patients) or 24 weeks (41 with pre-
vious failure with telaprevir or boceprevir plus PegIFN–RBV)
(Fig. 1A). Patients with cirrhosis were excluded.
Overall, 211 patients received treatment. Among HCV-G1
infected patients, 98% of 126 naïve patients and 98% of 41
patients who failed with protease inhibitors had an SVR at week
12 after the end of therapy (SVR12) (Fig. 1B). A total of 92% of 26
patients with HCV-G2 and 89% of 18 patients with HCV-G3 had a
SVR12. All patients had an HCV RNA level of less than 25 IU/ml by
week 4.
We have to be cautious regarding the results reported for HCV
genotype 3, the SVR rate was of 89% after 24 weeks of daclatasvir436 Journal of Hepatology 201plus sofosbuvir. This SVR appears to be similar to SVR obtained
with sofosbuvir plus ribavirin given during 24 weeks in genotype
3 non-cirrhotic patients [8].A highly efﬁcient regimen, even in ‘‘difﬁcult to cure’’ patients
Daclatasvir plus sofosbuvir was associated with high rates of SVR
among patients with characteristics that were previously known
to be associated with a poor response [9]. Impressively, this reg-
imen was highly efﬁcient in ‘‘difﬁcult to cure’’ patients. All
patients with prior failure with protease inhibitors had an SVR.
Among these patients, 71% had previous virologic breakthrough
or non-response, 80% were infected with subtype 1a, 98% had a
non-CC IFNL3 genotype (previously IL28B).
Virologic breakthrough and relapse was rare and was not
observed in any of the 193 patients infected with HCV genotype
1 or 2, despite pre-existing daclatasvir-resistant variants in 27
patients. Of the 5 patients infected with HCV-G1 or G2 without
SVR12 after treatment, 3 had missing data at week 12 but had
an SVR24 (including 1 who returned after the database lock)
and 2 were lost to follow-up. Among the 18 patients with HCV-
G3 infection, virologic relapse occurred in 1 of 5 patients with a
pre-existing daclatasvir resistant variant, and in a second patient,
who did not have pre-existing daclatasvir-resistant variants, an
HCV RNA level below 25 IU/ml was detected at weeks 8 and 10.
Because of low virus levels during treatment and an SVR12, the
role of viral variants could not be assessed. Sofosbuvir-resistant
variants were not detected in any of the patients.Ribavirin does not appear to be useful for this DAAs
combination
In this study, response rates were similar among patients treated
with or without RBV. These ﬁndings may reﬂect the antiviral
potency and high resistance barrier of the daclatasvir–sofosbuvir
combination and suggest that RBV is not required with every oral
DAA regimen. Of course, RBV is associated with anemia, and is
teratogenic, and therefore RBV-sparing regimen are desirable.
However, we cannot exclude, that in cost-effectiveness strategies,
RBV may have a role.4 vol. 61 j 435–438
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Fig. 1. Study design and results. (A) The study design. The study was an open-label, phase 2, randomized trial. Treatment-naive patients (groups A through F) were
randomly assigned in a 1:1:1 ratio to receive: (1) SOF for a 7-day lead-in, then DCV + SOF for 23 weeks (groups A and B), (2) DCV + SOF for 24 weeks (groups C and D) OR (3)
DCV + SOF + RBV for 24 weeks (groups E and F). GT1 patients were assigned to group A, C, or E, and GT2 or GT3 patients were assigned to group B, D, or F. Additionally, 123
GT1 patients were randomly assigned in a 1:1 ratio to DCV + SOF ± RBV. Eighty-two treatment-naive patients were assigned to group G or H for 12 weeks of treatment.
Forty-one prior PI failures were assigned to group I or J for 24 weeks of treatment. RBV, 1000–1200 mg/d, weight-based (GT1); 800 mg/d (GT 2/3); GT, genotype; DCV,
daclatasvir; SOF, sofosbuvir (GS-7977); RBV, ribavirin; TVR, telaprevir; BOC, boceprevir; (B) Results. In treatment-naive GT1, GT2, and GT3 patients, SVR12 rates ranging
from 89% to 100% were obtained in all groups receiving DCV + SOF, regardless of HCV genotype, viral subtype, treatment duration, IL28B genotype, or coadministration of
RBV. Overall 98% (164/167) GT1 achieved SVR12. Among GT1: 98% of GT1a and 100% of GT1b patients achieved SVR12. 93% non-CC and 98% non-CC IL28B GT1. 94% with
RBV and 98% without RBV. No patients experienced virologic breakthrough. For GT2 and GT3: 91% overall achieved SVR12. 92% of 26 of GT2 patients and 89% of 18 GT3
patients achieved SVR12. One patient with missing HCV RNA data at SVR12 later achieved SVR24 (group F). Another patient was lost to follow-up (group F). One GT3 patient
relapsed (group B). One GT3 had viral breakthrough (group B). In TVR- or BOC-based therapy failures, all 40 evaluable patients receiving DCV + SOF achieved SVR12 (98%; 1
patient had missing data). 33 patients previously failed TVR. 8 patients previously failed BOC. No patient experienced virologic breakthrough.
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Finally, once-daily, oral treatment with daclatasvir plus sofosbu-
vir was associated with high SVR rates in HCV-G1, 2, or 3 naïve
patients and in HCV-G1 patients with previous failure to proteaseJournal of Hepatology 201inhibitors. The development of resistance appears uncommon
with daclatasvir plus sofosbuvir.
Also, in the same issue of the NEJM, a phase IIb study with a
12-week DAAs combinations of protease inhibitor ABT-450 with
ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also4 vol. 61 j 435–438 437
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known as ABT-267) plus the non-nucleoside polymerase inhibitor
dasabuvir (also known as ABT-333), and RBV were associated
with high rates of SVR among HCV-G1 naïve patients and
among patients with failure to prior PegIFN-RBV therapy [3]. This
ABT-450 regimen has shown excellent results in phase III
[10–12]. The ﬁxed dose combination of sofosbuvir and ledipasvir
(NS5A inhibitor) has also demonstrated excellent results in
phase III [13–15].
Furthermore, the Cosmos study – evaluating simeprevir (pro-
tease inhibitor) plus sofosbuvir with or without RBV in GT1-naive
subjects and prior null-responders – reported also impressive
results [16–17]. It is a Phase IIa, randomized, open-label study
that evaluated 2 cohorts of patients. Cohort 1 (n = 80) random-
ized prior null-responders with Metavir scores F0–F2 and cohort
2 (n = 87) evaluated prior null-responder and naïve G1 individu-
als with F3–F4 scores.
Data from cohort 1 demonstrated that 93% and 96% of patients
with Metavir F0–F2 scores treated with simeprevir and sofosbu-
vir with or without ribavirin, respectively, for 12 weeks achieved
SVR12.
In cohort 2, 93% of participants assigned to simeprevir/sof-
osbuvir either alone or with RBV for 12 weeks achieved SVR12;
among those treated for 24 weeks, SVR12 rates were 93% and
100%, respectively.
In genotype 1a patients with the Q80K polymorphism at base-
line, 89% and 83% achieved SVR after 12 weeks of treatment with
and without ribavirin, respectively. The most common adverse
events in both treatment arms were fatigue, headache, nausea,
and insomnia. Two patients discontinued treatment due to
adverse events.
We have to recall that several of these phase 2 studies have
limitations: mainly the small number of patients limits an exact
evaluation of efﬁcacy and the possibility to detect adverse events.
Also, patients with cirrhosis are excluded, and they might be less
likely than those without cirrhosis to have a response, and also at
higher risk of side effects. Again, HCV-G4 patients are neglected,
and we have to recall that they represent around 40 million
worldwide, and account for the majority of new infection, with
no access to therapy, or in the best cases PegIFN plus RBV for
48 weeks with above 40% of SVR [18].
In conclusion, these fantastic data from different published
trials encourage us to remain very optimistic. We do hope that
the majority of HCV infected patients will become ‘‘easy-to-cure’’
and there will be more facilities to access treatment.Conﬂict of interest
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